Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Association Between Clinical Measures and Florbetapir F18 PET Neuroimaging in Mild or Moderate Alzheimer’s Disease Dementia
Michael M. Witte, Ph.D.; Paula Trzepacz, M.D.; Michael Case, M.S.; Peng Yu, Ph.D.; Helen Hochstetler, Pharm.D.; Mitchell Quinlivan, Ph.D.; Karen Sundell, B.S.; David Henley, M.D.
The Journal of Neuropsychiatry and Clinical Neurosciences 2014;:. doi:10.1176/appi.neuropsych.12120402
View Author and Article Information

From the Department of Neurosciences, Lilly USA, LLC, Indianapolis, IN (MMW, PT, MC, PY, HH); the Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN (PT, DH); Eli Lilly Australia, West Ryde, Australia (MQ); and Lilly Research Laboratories, Indianapolis, IN (KS, DH).

Send correspondence to Dr. Witte; e-mail: witte_michael_m@lilly.com

The authors report that they are employees of Eli Lilly and Company. All authors except Dr. Quinlivan are minor shareholders of Eli Lilly and Company.

Copyright © 2014 by the American Psychiatric Association

Received December 18, 2012; Revised March 21, 2013; Accepted April 22, 2013.

text A A A
PDF of the full text article.

Clinical diagnosis of Alzheimer’s disease (AD) is challenging with 20% or more of patients misdiagnosed, even by expert clinicians. We conducted a retrospective, cross-sectional analysis comparing baseline neuropsychiatric and other clinical characteristics in 199 expert-diagnosed mild and moderate AD dementia patients participating in industry-sponsored clinical trials of an investigational therapy, where 18% lacked florbetapir positron emission tomography (PET) evidence of AD neuropathology. Significant differences were found only for cognition and ApoE ε4 status, but the large degree of score overlap would preclude using these measures to predict AD misdiagnosis. This study highlights the value of amyloid PET when evaluating patients with seemingly typical AD.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
APA Practice Guidelines > Chapter 0.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 11.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 11.  >
Textbook of Traumatic Brain Injury, 2nd Edition > Chapter 3.  >
Textbook of Traumatic Brain Injury, 2nd Edition > Chapter 3.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles